The Tetraspanin CD9 Facilitates SARS-CoV-2 Infection and Brings Together Different Host Proteins Involved in SARS-CoV-2 Attachment and Entry into Host Cells
CD9 protein belongs to a family of proteins called tetraspanins, so named for their four-transmembrane-spanning architectures. These proteins are located in domains in the plasmatic membrane, called tetraspanin-enriched microdomains (TEMs). Several proteases and cellular receptors for virus entry cluster into TEMs, suggesting that TEMs are preferred virus entry portals. Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein mediates virus attachment and entry into cells by binding to human angiotensin-converting enzyme 2 (ACE-2). In addition, the secretory, type-I membrane-bound SARS-CoV-2 S protein is synthesized as a precursor (proS) that undergoes posttranslational cleavages by host cell proteases, such as furin and TMPRSS2. Moreover, it has been shown that neuropilin-1 (NRP1), which is known to bind furin-cleaved substrates, potentiates SARS-CoV-2 infectivity. Our results indicate that CD9 facilitates SARS-CoV-2 infection. In addition, we show how knocking out CD9 leads to a decrease in the expression of NRP1, a protein that improves SARS-CoV-2 infection. Furthermore, we show that CD9 colocalizes with ACE-2, NRP1, furin, and TMPRSS2 at the plasma membrane; that the absence of CD9 decreases the expression of these proteins on the plasma membrane CD9-enriched microdomains, and that CD9 interacts with ACE2. In conclusion, our data suggest that CD9 facilitates SARS-CoV-2 infection and that CD9 brings together different host proteins involved in SARS-CoV-2 attachment and entry into host cells, such as ACE2, NRP1, furin, and TMPRSS2. Importantly, the fact that a blocking antibody targeting CD9 can effectively reduce SARS-CoV-2 titers highlights not only the mechanistic role of CD9 in viral entry but also offers translational potential, suggesting that tetraspanin-targeting antibodies could be developed as therapeutic agents against SARS-CoV-2 and possibly other coronaviruses, with meaningful implications for clinical intervention.
Authors
- Vanessa Rivero
- Carlos López‐Larrea (ORCID: https://orcid.org/0000-0001-9988-1730)
- María Laura Sáiz (ORCID: https://orcid.org/0000-0002-3966-212X)
- Marta L. DeDiego (ORCID: https://orcid.org/0000-0002-7888-7372)
- Daniel Torralba (ORCID: https://orcid.org/0000-0002-7970-1277)
- Beatriz Suárez-Álvarez (ORCID: https://orcid.org/0000-0002-3431-4206)
Institutions
- Consejo Superior de Investigaciones Científicas (ES)
- Gobierno del Principado de Asturias (ES)
- Instituto de Salud Carlos III (ES)
- PharmaMar (Spain) (ES)
Publication Details
- Journal
- Viruses
- Published
- 2025-08-20
- DOI
- https://doi.org/10.3390/v17081141
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Gobierno del Principado de Asturias
- European Commission
- Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología
- Instituto de Salud Carlos III
- Agencia Estatal de Investigación